The study of drug susceptibility of the slow-growing mycobacterium M. xenopi
Abstract
The drug sensitivity of 74 strains of slow-growing Mycobacterium species M. xenopi was studied using the method of serial microdilutions – Sensititre SlowMyco (TREK DIAGNOSTIC Systems Ltd., UK).
It was found that this species of NTM is more often resistant to «basic» anti-tuberculosis drugs, and to other chemotherapy drugs used for the treatment of relevant mycobacterioses, according to different authors, may be sensitive or resistant.
The results of the studies described in this paper confirm these positions and give a more detailed description of the degree of sensitivity/ resistance of M. xenopi to the main drugs.
About the Authors
M. V. Makarova
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
E. N. Khachatourians
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
M. A. Krasnova
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
K. Yu. Galkina
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
L. D. Guntupova
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
A. O. Chizhova
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
V. I. Litvinov
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
References
1. Литвинов В.И., Богородская Е.М., Борисов С.Е. Нетуберкулезные микобактерии, микобактериозы // М.: МНПЦБТ. – 2014. – 254 с.
2. Оттен Т.Ф., Васильев А.В. Микобактериоз. – СПб.: Мед. пресса. – 2005. – 224 с.
3. Adle-Biassette H., Huerre M., Breton G. et al. Non tuberculous mycobacterial diseases //Ann. Pathol. – 2003. – Vol. 23. – Vol. 3. – P. 216-235.
4. Babady N., Hall L., Abbenyi A. et al. Evaluation of Mycobacterium avium complex clarithromycin susceptibility testing using SLOMYCO Sensititre panels and Just-One strips // J. Clin. Microbiol. – 2010. – Vol. 48. – N. 5. –P. 1749-1752.
5. Brown-Elliott B., Griffith D., Wallace R. Diagnosis of nontuberculous mycobacterial infections // J. Clin. Lab. Med. – 2002. – Vol. 22. – P. 911-925.
6. Brown-Elliott B., Nash K., Wallace R. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria // Clin. Microbiol. Rev. – 2012. – Vol. 25. – N. 3. – P. 545-582.
7. Carrillo M., Patsios D., Wagnetz U. et al. Comparison of the spectrum of radiologic and clinical manifestations of pulmonary disease caused by Mycobacterium avium complex and Mycobacterium xenopi // Can. Assoc. Radiol. J. – 2014. – Vol. 65. – N. 3. – P. 207-213.
8. CLSI. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes: approved standard: 2nd ed. CLSI document M24-A2. – Wayne, PA: Clinical and Laboratory Standards Institute, 2011. [Электронный ресурс]. URL: https://www.clsi.org/media/1463/m24a2_sample.pdf. (Дата обращения 01.06.2018).
9. Daley C. Mycobacterial infections// Semin. Respir. Crit. Care Med. – 2013. – Vol. 34. – N. 1. – P. 1.
10. Dauendorffer J., Laurain C., Weber M., Dailloux M. In vitro sensitivity of Mycobacterium xenopi to five antibiotics // Pathol. Biol. (Paris). – 2002. - Vol. 50. – N. 10. – P. 591-594.
11. Faress J., McKinney L., Semaan M. et al. Mycobacterium xenopi pneumonia in the southeastern United States // South Med. J. – 2003. –Vol. 96. – P. 596–599.
12. Gazzola L., Cesari M., Salerno F. et al. Clinical and therapeutic management of pulmonary Mycobacterium xenopi infection in HIV-positive patients // Clin. Infect. Dis. – 2004. – Vol. 38. – N. 11. – P. 1642-1644.
13. Glassroth J. Pulmonary disease due to nontuberculous mycobacteria // Chest. – 2008. – Vol. 133. – N. 1. – P. 243-251.
14. Griffith D., Aksamit T., Brown-Elliott B. et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases// Am. J. Respir. Crit. Care Med. – 2007. – Vol. 175. – N. 4. – P. 367-416.
15. Gupta A., McBride A., Holder K. et al. Pathology in practice.Severe pyogranulomatous pneumonia, enteritis, and lymphadenitis with numerous acid-fast bacteria (M. xenopi) // J. Am. Vet. Med. Assoc. – 2012. – Vol. 240. – N. 12. – P. 1427-1429.
16. Heifets L. Drug susceptibility in the chemotherapy of mycobacterial infections. – CRC Press. Boca Raton Ann Arbor Boston. London. – 2000. – 212 p.
17. Heifets L. Mycobacterial infections caused by nontuberculous mycobacteria // Semin. Respir. Crit. Care Med. – 2004. – Vol. 25. – N. 3. – P. 283-295.
18. Hoefsloot W., van Ingen J., Andrejak C. et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study // Eur. Respir. J. – 2013. – Vol. 42. – N. 6. – P. 1604-1613.
19. Hombach M., Somoskövi A., Hömke R. et al. Drug susceptibility distributions in slowly growing non-tuberculous mycobacteria using MGIT 960 TB eXiST // Int. J. Med. Microbiol. – 2013. – Vol. 303. – N. 5. – P. 270-276.
20. Jenkins P., Campbell I. Research Committee of the British Thoracic Society. Pulmonary disease caused by Mycobacterium xenopi in HIV-negative patients: five-year follow-up of patients receiving standardized treatment // Respir. Med. – 2003. – Vol. 97. – P. 439–444.
21. Katoch V. Infections due to non-tuberculous mycobacteria (NTM) // Indian. J. Med. Res. – 2004. – Vol. 120. – P. 290-304.
22. Matsui Y., Tamura A., Nagayama N. et al. Review of pulmonary Mycobacterium xenopi infection cases: 11 cases of our own and 18 other cases reported in Japan // Kekkaku. – 2010. – Vol. 85. – N. 8. – P. 647-653.
23. Prevots D., Marras T. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review// Clin. Chest. Med. – 2015. – Vol. 36. – N. 1. – P. 13-34.
24. Stout J., Koh W., Yew W. Update on pulmonary disease due to non-tuberculous mycobacteria // Int. J. Infect. Dis. – 2016. – Vol. 45. – P. 123-134.
25. Tortoli E. Clinical manifestations of nontuberculous mycobacteria infections // Clin. Microbiol. Infect. – 2009. – Vol. 15. – N. 10. – P. 906-910.
26. van Ingen J., Hoefsloot W., de Lange W. et al. Nontuberculous mycobacteria: clinically relevan // Ned. Tijdschr. Geneeskd. – 2010(a). – 154:A1178.
27. van Ingen J., van der Laan T., Dekhuijzen R. et al. In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands // Int. J. Antimicrob. Agents. – 2010(b). – Vol. 35. – N. 2. – P. 169-173.
28. van Ingen J., Kuijper E. Drug susceptibility testing of nontuberculous mycobacteria // Future Microbiol. – 2014. – Vol. 9. – N. 9. – P. 1095-1110.
29. Varadi R., Marras T. Pulmonary Mycobacterium xenopi infection in non-HIV-infected patients: a systematic review // Int. J. Tuberc. Lung. Dis. – 2009. – Vol. 13. – N. 10. – P. 1210-1218.
30. Woods G. Susceptibility testing for mycobacteria // Clin. Infect. Dis. – 2000. – Vol. 31. – N. 5. – P. 1209-1215
Review
For citations:
Makarova M.V., Khachatourians E.N., Krasnova M.A., Galkina K.Yu., Guntupova L.D., Chizhova A.O., Litvinov V.I. The study of drug susceptibility of the slow-growing mycobacterium M. xenopi. Tuberculosis and socially significant diseases. 2018;(3):26-31. (In Russ.)
Views:
31
Email this article 